Fedha

Hisa unazofuatilia
KLBF:IDX
Kalbe Farma Tbk PT
IDR 780.00
0.00%
(0.00) Siku 1
14 Okt, 16:11:07 GMT +7  ·   IDR
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya KLBF...
Fungua
IDR 780
Juu
IDR 795
Chini
IDR 765
Mtaji wa soko
36.51T
Wastani wa kiasi cha mauzo
65.90M
Kiasi cha mauzo ya hisa
44.50M
Gawio
2.56%
Mgawo wa faida wa kila robo mwaka
IDR 5
Tarehe ya kutojumuisha gawio
4 Jun 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
9.80
Juu kwa wiki 52
IDR 1,345
Chini kwa wiki 52
IDR 630
EPS
IDR 80
Hisa za wawekezaji
46.81B
Idadi ya wafanyakazi
elfu 13
Fungua
IDR 780
Juu
IDR 795
Chini
IDR 765
Mtaji wa soko
36.51T
Wastani wa kiasi cha mauzo
65.90M
Kiasi cha mauzo ya hisa
44.50M
Gawio
2.56%
Mgawo wa faida wa kila robo mwaka
IDR 5
Tarehe ya kutojumuisha gawio
4 Jun 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
9.80
Juu kwa wiki 52
IDR 1,345
Chini kwa wiki 52
IDR 630
EPS
IDR 80
Hisa za wawekezaji
46.81B
Idadi ya wafanyakazi
elfu 13
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Kuhusu Kalbe Farma Tbk PT
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazielfu 12.8
Lilianzishwa10 Sep 1966
Makao makuu-
Sekta-
Ripoti ya mwisho
28 Jul 2026
Kipindi cha Kifedha
Robo2 2026
IDR 19.68 / IDR 20.14
-2.28%hujafikia
Mapato dhidi ya makadirio (IDR)
9.80T / -
Mkutano pepe wa kujadili mapato ya robo ya Robo ya 2 ya mwaka wa fedha wa 2026
Inasubiri mkutano pepe wa kujadili mapato
Kwa muhtasari
Maarifa kutoka kwenye ripoti na habari za hivi punde
Ripoti za awaliThamani zote katika IDR
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika IDR
Sep 2025
Des 2025
Mac 2026
Jun 2026
Mapato
8.91T
9.34T
9.68T
9.80T
Gharama ya bidhaa zilizouzwa
5.46T
5.92T
6.02T
6.25T
Gharama ya mapato
5.46T
5.92T
6.02T
6.25T
Gharama za utafiti na maendeleo
98.31B
160.88B
113.14B
122.60B
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
2.51T
1.95T
2.23T
2.27T
Gharama ya uendeshaji
2.60T
2.14T
2.33T
2.39T
Jumla ya gharama za uendeshaji
8.06T
8.05T
8.36T
8.64T
Mapato ya uendeshaji
851.77B
1.28T
1.32T
1.16T
Mapato mengine yasiyo ya uendeshaji
-3.78B
-4.17B
-3.63B
-3.74B
EBT ikijumuisha vipengee visivyo vya kawaida
877.87B
1.30T
1.36T
1.19T
EBT bila kujumuisha vipengee visivyo vya kawaida
888.55B
1.30T
1.36T
1.18T
Gharama ya kodi ya mapato
211.19B
252.81B
303.84B
271.57B
Kiwango cha kodi kinachotumika
24.06%
19.41%
22.40%
22.80%
Gharama nyingine za uendeshaji
-7.23B
31.35B
-10.02B
2.13B
Mapato halisi
656.41B
1.03T
1.03T
890.54B
Kiwango cha faida halisi
7.37%
11.07%
10.63%
9.09%
Mapato kwa kila hisa
14.44
22.72
22.74
19.68
Mapato ya riba na uwekezaji
41.31B
40.43B
32.07B
43.61B
Gharama ya riba
-9.69B
-5.77B
-4.61B
-6.78B
Jumla ya gharama halisi za riba
31.62B
34.66B
27.46B
36.83B
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
1.05T
1.45T
1.51T
1.20T
Faida au hasara kutokana na uuzaji wa vipengee
-
-
-
-
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
Programu za Google